ACHV - Achieve Life Sciences, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Vancouver,
Canada
Type: Equity
ACHV price evolution
ACHV
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.55 | $19.92 | $25.07 | $16.51 |
| Short term investments | ||||
| Net receivables | $0.11 | $0.08 | $0.35 | $0.09 |
| Inventory | ||||
| Total current assets | $16.98 | $21.9 | $26.38 | $18.22 |
| Long term investments | $0.09 | |||
| Property, plant & equipment | $0.07 | $0.08 | $0.1 | $0.11 |
| Goodwill & intangible assets | $2.23 | $2.29 | $2.34 | $2.4 |
| Total noncurrent assets | $2.39 | $2.44 | $2.54 | $2.57 |
| Total investments | $0.09 | |||
| Total assets | $19.37 | $24.34 | $28.91 | $20.8 |
| Current liabilities | ||||
| Accounts payable | $0.62 | $0.64 | $0.36 | $1.06 |
| Deferred revenue | ||||
| Short long term debt | $16.73 | $0.06 | $0.06 | $16.43 |
| Total current liabilities | $20.81 | $4.08 | $3.45 | $20.3 |
| Long term debt | $0.01 | $16.22 | $15.77 | $0.05 |
| Total noncurrent liabilities | $0.01 | $16.22 | $15.77 | $0.05 |
| Total debt | $16.73 | $16.28 | $15.83 | $16.48 |
| Total liabilities | $20.82 | $20.3 | $19.22 | $20.36 |
| Shareholders' equity | ||||
| Retained earnings | -$165.75 | -$160.28 | -$153.17 | -$144.93 |
| Other shareholder equity | $0 | $0 | $0 | $0 |
| Total shareholder equity | -$1.45 | $4.04 | $9.7 | $0.44 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.55 | $24.77 | $43.02 | $35.9 |
| Short term investments | ||||
| Net receivables | $0.11 | $0.1 | $0.15 | |
| Inventory | ||||
| Total current assets | $16.98 | $27.33 | $44.59 | $36.98 |
| Long term investments | $0.09 | $0.07 | ||
| Property, plant & equipment | $0.07 | $0.13 | $0.06 | $0.19 |
| Goodwill & intangible assets | $2.23 | $2.45 | $2.67 | $2.9 |
| Total noncurrent assets | $2.39 | $2.64 | $2.92 | $3.32 |
| Total investments | $0.09 | $0.07 | ||
| Total assets | $19.37 | $29.97 | $47.52 | $40.3 |
| Current liabilities | ||||
| Accounts payable | $0.62 | $1.66 | $0.84 | $0.33 |
| Deferred revenue | ||||
| Short long term debt | $16.73 | $16.13 | $0.07 | $0.09 |
| Total current liabilities | $20.81 | $21.6 | $4.55 | $2.94 |
| Long term debt | $0.01 | $0.07 | $14.92 | $0.08 |
| Total noncurrent liabilities | $0.01 | $0.07 | $14.92 | $0.08 |
| Total debt | $16.73 | $16.2 | $14.99 | $0.17 |
| Total liabilities | $20.82 | $21.67 | $19.47 | $3.01 |
| Shareholders' equity | ||||
| Retained earnings | -$165.75 | -$135.94 | -$93.59 | -$60.43 |
| Other shareholder equity | $0 | $0 | $0 | $0 |
| Total shareholder equity | -$1.45 | $8.3 | $28.04 | $37.29 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $2.11 | $3.58 | $4.58 | $5.53 |
| Selling, general & administrative | $2.27 | $2.99 | $3.13 | $3.04 |
| Total operating expenses | $4.39 | $6.57 | $7.71 | $8.58 |
| Operating income | -$4.39 | -$6.57 | -$7.71 | -$8.58 |
| Income from continuing operations | ||||
| EBIT | -$4.69 | -$6.33 | -$7.53 | -$8.42 |
| Income tax expense | ||||
| Interest expense | $0.79 | $0.78 | $0.71 | $0.57 |
| Net income | ||||
| Net income | -$5.48 | -$7.11 | -$8.24 | -$8.99 |
| Income (for common shares) | -$5.48 | -$7.11 | -$8.24 | -$8.99 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $15.81 | $30.08 | $23.97 | $6.88 |
| Selling, general & administrative | $11.44 | $10.72 | $9.13 | $7.87 |
| Total operating expenses | $27.25 | $40.8 | $33.09 | $14.75 |
| Operating income | -$27.25 | -$40.8 | -$33.09 | -$14.75 |
| Income from continuing operations | ||||
| EBIT | -$26.96 | -$40.56 | -$33.15 | -$14.73 |
| Income tax expense | ||||
| Interest expense | $2.85 | $1.79 | ||
| Net income | ||||
| Net income | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| Income (for common shares) | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$5.48 | -$7.11 | -$8.24 | -$8.99 |
| Operating activities | ||||
| Depreciation | $0.06 | $0.06 | $0.06 | $0.06 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | -$0.01 | $1.17 | $1.19 | $1.08 |
| Total cash flows from operations | -$4.36 | -$5.14 | -$6.68 | -$8.3 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | |||
| Investments | ||||
| Total cash flows from investing | -$0.01 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.45 | $0.05 | ||
| Net borrowings | ||||
| Total cash flows from financing | $15.23 | $0.05 | ||
| Effect of exchange rate | -$0 | -$0 | $0 | -$0 |
| Change in cash and equivalents | -$4.37 | -$5.15 | $8.56 | -$8.26 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$29.82 | -$42.35 | -$33.15 | -$14.73 |
| Operating activities | ||||
| Depreciation | $0.23 | $0.24 | $0.25 | $0.26 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.44 | $3.27 | $2.19 | $1.29 |
| Total cash flows from operations | -$24.48 | -$37.55 | -$29.44 | -$13.47 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.02 | ||
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.02 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.5 | $19.36 | $21.68 | $32.73 |
| Net borrowings | -$0.02 | $14.93 | ||
| Total cash flows from financing | $15.28 | $19.3 | $36.61 | $32.68 |
| Effect of exchange rate | -$0 | $0 | -$0 | |
| Change in cash and equivalents | -$9.22 | -$18.25 | $7.17 | $19.19 |
News
Fundamentals
| Market cap | $96.09M |
|---|---|
| Enterprise value | $97.28M |
| Shares outstanding | 21.17M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$26.73M |
| EBIT | -$26.96M |
| Net Income | -$29.82M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.22 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -3.64 |
| EV/EBIT | -3.61 |
| P/S ratio | N/A |
| P/B ratio | -66.18 |
| Book/Share | -0.07 |
| Cash/Share | 0.73 |
| EPS | -$1.41 |
|---|---|
| ROA | -127.66% |
| ROE | -936.69% |
| Debt/Equity | -14.38 |
|---|---|
| Net debt/EBITDA | -0.20 |
| Current ratio | 0.82 |
| Quick ratio | 0.82 |